+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The US Anesthesia Drugs and Devices Market: Analysis By segment, By Type, By Drug product, By Device Product, Size And Trends With Impact of COVID-19 and Forecast up to 2027

  • PDF Icon

    Report

  • 119 Pages
  • November 2022
  • Region: United States
  • Daedal Research
  • ID: 5414957
The US anesthesia drugs and devices market in 2021 was valued at US$5.99 billion. The market value is predicted to reach US$8.88 billion by 2027. Anesthesia is the use of medicines to prevent pain during surgery and other procedures. They may be given by injection, inhalation, topical lotion, spray, eye drops, or skin patch. Anesthesia can cause one to have a loss of feeling or awareness.

The market is expected to grow at a CAGR of 6.80% during the forecast period of 2022-2027. Due to increasing number of surgeries, aging population with increasing chronic conditions, and advancements in anesthesia technologies, the market for anesthesia drugs and devices would grow in the years to come.

Market Segmentation Analysis:

- By Segment: The report provides the bifurcation of the market into two categories based on the segment: anesthesia drugs and anesthesia devices. In 2021, anesthesia drugs segment held a major share of more than 55% in the market. On the other hand, the anesthesia devices segment is expected to grow at a significant CAGR in the forthcoming years owing to the rising healthcare expenditure in the region.
- By Type: On the basis of type, the US anesthesia drugs market is divided into three types namely general, local and other anesthesia. In 2021, general anesthesia drug segment held a major share of more than 39% in the market. This was being followed by local anesthesia drugs. R&D activities in the pharmaceutical industry to formulate novel anesthesia drug is expected to provide remunerative opportunities for expansion of the US other anesthesia drugs market during forecast period.
- By Device Product: The report provides the bifurcation of the market into three segments based on the device product: advanced, basic and integrated. In 2021, advanced segment held a major share of 62% in the market. This was being followed by integrated anesthesia device. The constant development in the field of the anesthesia monitoring devices and high demand for the better monitoring devices are also anticipated to push the growth in the US advanced anesthesia monitoring devices market.
- By Drug Product: The report provides the bifurcation of the market into seven segments based on the drug product: Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine and Other Local Anesthetics. In 2021, Lidocaine anesthesia drug segment held a major share of 32% in the market. This was being followed by Bupivacaine, Ropivacaine. The market is anticipated to propel during forecasted years owing to the expanding patient population and the rise in medical and surgical procedures.

Market Dynamics:

- Growth Drivers: One of the most important factors impacting the US anesthesia drugs and devices market is rising geriatric population. Steady growth in aging population raised the incidence of the chronic condition over the past decade. This had caused increasing number of surgical procedures of elderly patients. Additionally, benefits such as advances in surgery and anesthesia can improve function and quality of life for older patients also supported market growth. Thus, the positive acceleration in aging population consequently supported the growth of the anesthesia drugs and devices market in the US. Furthermore, the market has been growing over the past few years, due to factors such as growing healthcare expenditure, increase in monitored anesthesia use, increase in number of approval for anesthesia drugs and many other factors.
- Challenges: However, the market has been confronted with some challenges specifically, lack of skilled anesthesiologist, etc.
- Trends: The market is projected to grow at a fast pace during the forecast period, due to various latest trends such as the escalating establishment of ambulatory surgical centers (ASC), technological enhancement of anesthesia devices, etc. Technology upgradation such as Closed loop TIVA and Ultrasound-Guided Regional Anesthesia (UGRA) are expected to propel the US drug and devices market during forecasted years.

Impact Analysis of COVID-19 and Way Forward:

The surge in the coronavirus virus cases worldwide resulted in the utilization of all available intensive care unit (ICU) ventilators and anesthesia machines for longer-term ventilation of COVID-19 or other critically ill patients. In hospitals, the administration of inhalation anesthetics for sedation during longer-term ventilation with anesthesia machines was also increased. The effect of COVID-19 on surgical procedures is far and wide, going from the labor force and staffing issues, procedural prioritization, and viral transmission hazard intraoperatively. Due to the emergence of the pandemic situation, demand for anesthesia drugs decreased slightly in 2020, resulting in surgeries being postponed or canceled. However, as activities resume, all of the elective surgeries that had been postponed are now being completed, increasing anesthesia drug consumption.

Competitive Landscape:

The US anesthesia drugs and devices market is competitive and consists of several major players. The key players in the US anesthesia drugs and devices market are:

- KKR & Co. Inc. (Envision Healthcare Corporation)
- Baxter International Inc.
- Blackstone (TeamHealth)
- Becton, Dickinson and Company
- Braun (B. Braun Avitum AG)
- 3M Company
- Abbvie Inc.
- Teleflex Incorporated
- Drägerwerk AG & Co. KGaA
- AstraZeneca Plc
- Abbott Laboratories
- General Electric Company
- ICU Medical, Inc
- SunMed LLC

Some of the strategies among key players in the market for the US anesthesia drugs and devices market are mergers, acquisitions, and collaborations. For instance, in 2022, Teleflex Incorporated announced the company has completed the previously announced acquisition of Standard Bariatrics, Inc., which has commercialized an innovative powered stapling technology for bariatric surgery. Whereas, B. Braun announced that with the full integration of Intermedt Medizin & Technik GmbH into the Group, B. Braun had completed the extensive product portfolio of the B. Braun Avitum division as a systems provider for extracorporeal blood treatment (dialysis).

Table of Contents


1. Executive Summary
2. Introduction
2.1 Anesthesia: An Overview
2.1.1 Definition of Anesthesia
2.2 Anesthesia Segmentation: An Overview
2.2.1 Anesthesia Segmentation
3. Market Analysis
3.1 The US Anesthesia Drugs and Devices Market: An Analysis
3.1.1 The US Anesthesia Drugs and Devices Market: An Overview
3.1.2 The US Anesthesia Drugs and Devices Market by Value
3.1.3 The US Anesthesia Drugs and Devices Market by Segment (Anesthesia Drugs And Anesthesia Devices)
3.2 The US Anesthesia Drugs and Devices Market: Segment Analysis
3.2.1 The US Anesthesia Drugs Market by Segment: An Overview
3.2.2 The US Anesthesia Drugs Market by Value
3.2.3 The US Anesthesia Drugs Market by Type (General, Local And Other Anesthesia)
3.2.4 The US Anesthesia Devices Market by Value
3.2.5 The US Anesthesia Devices Market by Product (Advanced, Basic And Integrated)
3.3 The US Anesthesia Drugs Market: Type Analysis
3.3.1 The US Anesthesia Drugs Market by Type: An Overview
3.3.2 The US General Anesthesia Drugs Market by Value
3.3.3 The US Local Anesthesia Drugs Market by Value
3.3.4 The US Local Anesthesia Drugs Market by Product (Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine and Other Local Anesthetics)
3.3.5 The US Other Anesthesia Drugs Market by Value
3.4 The US Local Anesthesia Drugs Market: Product Analysis
3.4.1 The US Local Anesthesia Drugs Market by Product: An Overview
3.4.2 The US Lidocaine Anesthesia Drugs Market by Value
3.4.3 The US Bupivacaine Anesthesia Drugs Market by Value
3.4.4 The US Ropivacaine Anesthesia Drugs Market by Value
3.4.5 The US Prilocaine Anesthesia Drugs Market by Value
3.4.6 The US Benzocaine Anesthesia Drugs Market by Value
3.4.7 The US Chloroprocaine Anesthesia Drugs Market by Value
3.4.8 The US Other Local Anesthesia Drugs Market by Value
3.5 The US Anesthesia Devices Market: Product Analysis
3.5.1 The US Anesthesia Devices Market by Product: An Overview
3.5.2 The US Advanced Anesthesia Devices Market by Value
3.5.3 The US Integrated Anesthesia Devices Market by Value
3.5.4 The US Basic Anesthesia Devices Market by Value
4. Impact of COVID-19
4.1 Impact of COVID-19 on Anesthesia Drugs And Devices Market
4.2 Response of Industry
4.3 The US Number of COVID-19 Total Cases
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Rising Geriatric Population
5.1.2 Growing Healthcare Expenditure
5.1.3 Increase in Monitored Anesthesia Use
5.1.4 Increase In Number Of Approval For Anesthesia Drugs
5.2 Challenges
5.2.1 Side Effects of Anesthesia
5.2.2 Lack of Skilled Anesthesiologist
5.3 Market Trends
5.3.1 Escalating Establishment of Ambulatory Surgical Centers (ASC)
5.3.2 Technological Enhancement of Anesthesia Devices
6. Competitive Landscape
6.1 The US Anesthesia Hospital Players by Market Share
6.2 The US Anesthesia Service Market by Other Private Providers
6.3 The US Anesthesiology Service Market Players by Services
7. Company Profiles
7.1 KKR & Co. Inc. (Envision Healthcare Corporation)
7.1.1 Business Overview
7.1.2 Business Strategy
7.2 Baxter International Inc.
7.2.1 Business Overview
7.2.2 Operating Segment
7.2.3 Business Strategy
7.3 Blackstone (TeamHealth)
7.3.1 Business Overview
7.3.2 Business Strategy
7.4 Becton, Dickinson and Company
7.4.1 Business Overview
7.4.2 Operating Segment
7.4.3 Business Strategy
7.5 Braun (B. Braun Avitum AG)
7.5.1 Business Overview
7.5.2 Sales by Division
7.5.3 Business Strategy
7.6 3M Company
7.6.1 Business Overview
7.6.2 Operating Segment
7.6.3 Business Strategy
7.7 Abbvie Inc.
7.7.1 Business Overview
7.7.2 Net Revenue by Therapeutic Area
7.7.3 Business Strategy
7.8 Teleflex Incorporated
7.8.1 Business Overview
7.8.2 Operating Segment
7.8.3 Business Strategy
7.9 Drägerwerk AG & Co. KGaA
7.9.1 Business Overview
7.9.2 Net Sales by Division
7.9.3 Business Strategy
7.10 AstraZeneca Plc
7.10.1 Business Overview
7.10.2 Total Revenue by Disease Areas
7.10.3 Business Strategies
7.11 Abbott Laboratories
7.11.1 Business Overview
7.11.2 Operating Segment
7.11.3 Business Strategy
7.12 General Electric Company
7.12.1 Business Overview
7.12.2 Operating Segment
7.12.3 Business Strategy
7.13 ICU Medical, Inc.
7.13.1 Business Overview
7.13.2 Revenues by Geography
7.13.3 Business Strategy
7.14 SunMed LLC
7.14.1 Business Overview
7.14.2 Business Strategy
List of Figures
Figure 1: Anesthesia: Side Effects
Figure 2: Anesthesia Segmentation
Figure 3: The US Anesthesia Drugs and Devices Market by Value; 2017-2021 (US$ Billion)
Figure 4: The US Anesthesia Drugs and Devices Market by Value; 2022-2027 (US$ Billion)
Figure 5: The US Anesthesia Drugs Market by Segment; 2021 (Percentage, %)
Figure 6: The US Anesthesia Drugs Market by Value; 2017-2021 (US$ Billion)
Figure 7: The US Anesthesia Drugs Market by Value; 2022-2027 (US$ Billion)
Figure 8: The US Anesthesia Drugs Market by Type; 2021 (Percentage, %)
Figure 9: The US Anesthesia Devices Market by Value; 2017-2021 (US$ Billion)
Figure 10: The US Anesthesia Devices Market by Value; 2022-2027 (US$ Billion)
Figure 11: The US Anesthesia Devices Market by Product; 2021 (Percentage, %)
Figure 12: The US General Anesthesia Drugs Market by Value; 2017-2021 (US$ Billion)
Figure 13: The US General Anesthesia Drugs Market by Value; 2022-2027 (US$ Billion)
Figure 14: The US Local Anesthesia Drugs Market by Value; 2017-2021 (US$ Billion)
Figure 15: The US Local Anesthesia Drugs Market by Value; 2022-2027 (US$ Billion)
Figure 16: The US Local Anesthesia Drugs Market by Product; 2021 (Percentage, %)
Figure 17: The US Other Anesthesia Drugs Market by Value; 2017-2021 (US$ Million)
Figure 18: The US Other Anesthesia Drugs Market by Value; 2022-2027 (US$ Billion)
Figure 19: The US Lidocaine Anesthesia Drugs Market by Value; 2017-2021 (US$ Million)
Figure 20: The US Lidocaine Anesthesia Drugs Market by Value; 2022-2027 (US$ Million)
Figure 21: The US Bupivacaine Anesthesia Drugs Market by Value; 2017-2021 (US$ Million)
Figure 22: The US Bupivacaine Anesthesia Drugs Market by Value; 2022-2027 (US$ Million)
Figure 23: The US Ropivacaine Anesthesia Drugs Market by Value; 2017-2021 (US$ Million)
Figure 24: The US Ropivacaine Anesthesia Drugs Market by Value; 2022-2027 (US$ Million)
Figure 25: The US Prilocaine Anesthesia Drugs Market by Value; 2017-2021 (US$ Million)
Figure 26: The US Prilocaine Anesthesia Drugs Market by Value; 2022-2027 (US$ Million)
Figure 27: The US Benzocaine Anesthesia Drugs Market by Value; 2017-2021 (US$ Million)
Figure 28: The US Benzocaine Anesthesia Drugs Market by Value; 2022-2027 (US$ Million)
Figure 29: The US Chloroprocaine Anesthesia Drugs Market by Value; 2017-2021 (US$ Million)
Figure 30: The US Chloroprocaine Anesthesia Drugs Market by Value; 2022-2027 (US$ Million)
Figure 31: The US Other Local Anesthesia Drugs Market by Value; 2017-2021 (US$ Million)
Figure 32: The US Other Local Anesthesia Drugs Market by Value; 2022-2027 (US$ Million)
Figure 33: The US Advanced Anesthesia Devices Market by Value; 2017-2021 (US$ Billion)
Figure 34: The US Advanced Anesthesia Devices Market by Value; 2022-2027 (US$ Billion)
Figure 35: The US Integrated Anesthesia Devices Market by Value; 2017-2021 (US$ Million)
Figure 36: The US Integrated Anesthesia Devices Market by Value; 2022-2027 (US$ Million)
Figure 37: The US Basic Anesthesia Devices Market by Value; 2017-2021 (US$ Million)
Figure 38: The US Basic Anesthesia Devices Market by Value; 2022-2027 (US$ Million)
Figure 39: The US Number of COVID-19 Total Cases, 2020-2022 (Million)
Figure 40: The US Old Age Population (65 years and Older); 2016-2021 (Percentage,%)
Figure 41: The US National Health Expenditure; 2021-2028 (US$ Trillion)
Figure 42: The US Ambulatory Surgical Centers; 2020-2025 (US$ Billion)
Figure 43: The US Anesthesia Hospital Players by Market Share; 2021 (Percentage, %)
Figure 44: Baxter International Inc. Net Sales by Segment; 2021 (Percentage, %)
Figure 45: Becton, Dickinson and Company Revenues by Segment; 2021 (Percentage, %)
Figure 46: B. Braun Sales by Division; 2021 (Percentage, %)
Figure 47: 3M Company Net Sales by Segment; 2021 (Percentage, %)
Figure 48: Abbvie Inc. Net Revenue by Therapeutic Area; 2021 (Percentage, %)
Figure 49: Teleflex Incorporated Net Revenues by Segments; 2021 (Percentage, %)
Figure 50: Drägerwerk AG & Co. KGaA Net Sales by Division; 2021 (Percentage, %)
Figure 51: AstraZeneca Total Revenue by Disease Areas; 2021 (Percentage, %)
Figure 52: Abbott Laboratories Sales by Segment; 2021 (Percentage, %)
Figure 53: General Electric Company Revenue by Segment; 2021 (Percentage,%)
Figure 54: ICU Medical, Inc. Revenues by Geography; 2021 (Percentage,%)
Table 1: The US Anesthesia Service Market by Other Private Providers
Table 2: The US Anesthesiology Service Market Players by Services

Companies Mentioned

  • KKR & Co. Inc. (Envision Healthcare Corporation)
  • Baxter International Inc.
  • Blackstone (TeamHealth)
  • Becton, Dickinson and Company
  • Braun (B. Braun Avitum AG)
  • 3M Company
  • Abbvie Inc.
  • Teleflex Incorporated
  • Drägerwerk AG & Co. KGaA
  • AstraZeneca Plc
  • Abbott Laboratories
  • General Electric Company
  • ICU Medical, Inc
  • SunMed LLC